A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML
Status:
Active, not recruiting
Trial end date:
2022-11-21
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of midostaurin in combination with
daunorubicin/cytarabine induction, high dose cytarabine consolidation and midostaurin single
agent continuation therapy in newly diagnosed patients with FLT3-mutated acute myeloid
leukemia (AML).